Article PDF
Références
Amado RG, Wolf M, Peeters M, et al (2008). Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626–1634
Bonnes pratiques pour la recherche à visée théranostique de mutations somatiques dans les tumeurs solides. Institut national du cancer. http://www.e-cancer.fr/soins/plates-formes-hospitalieresdegénétiquemoléculaire
Van Cutsem E, Köhne CH, Láng I, et al (2011). Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29:2011–2019
Douillard JY, Oliner KS, Siena SJ, et al (2013). Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023–1034
Schwartzberg LS, Rivera F, Karthaus M, et al (2013). Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC). J Clin Oncol 31 (Suppl. abstr 3631)
Peeters M, Oliner KS, Parker A, et al (2013). Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19:1902–1912
Patterson SD, Peeters M, Siena S, et al (2013). Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408). J Clin Oncol 31 (Suppl. abstr 3617)
Douillard JY, Siena S, Cassidy J, et al (2010). Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697–4705
Bokemeyer C, Van Cutsem E, Rougier P, et al (2012). Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466–1475
Stintzing S, Jung A, Rossius L, et al (2013). Analysis of KRAS/ NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type KRAS (exon 2) metastatic colorectal cancer patients. Eur J Cancer 49(suppl.3 LBA17)
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Bibeau, F. Médecine personnalisée en oncologie digestive : vers de nouveaux horizons. Colon Rectum 8, 75–76 (2014). https://doi.org/10.1007/s11725-014-0514-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11725-014-0514-x